Acute Myeloid Leukemia (AML)

Reshma Ramlal, MD

Institution
Moffitt Cancer Center
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
About

Dr. Reshma Ramlal is a hematologist-oncologist at the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida. She specializes in bone marrow transplantation and cellular immunotherapy, with a clinical and research focus on allogeneic transplantation for myeloid malignancies, including acute myeloid leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms. She is particularly recognized for advancing safe and effective transplantation in the elderly population, offering individualized treatment plans that emphasize both survival and quality of life. In her clinical

Treatments for High Risk MDS and Secondary AML, AAMDSIF 2026 International Bone Marrow Failure Scientific Symposium

Thumbnail for video Watch Now

Topic(s)
Acute Myeloid Leukemia (AML)
Myelodysplastic Syndromes (MDS)
Presenter(s)
Hetty Carraway, M.D.
Amer Zeidan, MBBS
Mikkael Sekeres, MD, MS
Andrew Brunner
Maximilian Stahl, MD
Richard M. Stone, MD
Amer Zeidan, MBBS
The session was recorded at the AAMDSIF 2026 International Bone Marrow Failure Scientific Symposium, Co-Chairs Hetty Carraway, MD, MBA, FACP, and Amer Zeidan, MBBS, MD. Topics and Speakers included: Key Concepts in Clinical Trial Design For HR-MDS: Lessons Learned from Phase 3 -…

Health-Related Quality of Life, AAMDSIF 2026 International Bone Marrow Failure Scientific Symposium

Thumbnail for video Watch Now

Presenter(s)
Namrata Chandhok, MD
Thomas LeBlanc, MD, MA
Fabio Efficace, PhD
Alison R. Kavanaugh
Pamela C. Egan, MD
Wil L. Santivasi, MD
The session was recorded at the AAMDSIF 2026 International Bone Marrow Failure Scientific Symposium, Co-Chairs Namrata Chandhok, MD, and Thomas LeBlanc, MD, MA Topics and speakers included: How can we measure quality of life in MDS, to inform interventions? - Fabio Efficace, PhD…

MDS and Secondary AML Pathophysiology, AAMDSIF 2026 International Bone Marrow Failure Scientific Symposium

Thumbnail for video Watch Now

Topic(s)
Acute Myeloid Leukemia (AML)
Myelodysplastic Syndromes (MDS)
Presenter(s)
Jaroslaw Maciejewski, MD, PhD
Valeria Visconte, PhD
Lukasz Gondek, M.D., Ph.D.
Guillermo Montalban Bravo, MD
Aly Karsan, MD
This session was recorded at the AAMDSIF 2026 International Bone Marrow Failure Scientific Symposium, Co-Chairs Jaroslaw Maciejewski, MD, PhD, and Maria (Ken) Figueroa, MD. Session topics and speakers included: Objective pathogenetically driven molecular classification of MDS and…

Non-Transplant Therapies for Marrow Failure, AAMDSIF 2026 International Bone Marrow Failure Scientific Symposium

Thumbnail for video Watch Now

Presenter(s)
Carlos DeCastro, MD
Phil Scheinberg, MD
Regis Peffault de Latour, MD, PhD
Julian Sevilla, MD, PhD
Kasiani Myers, MD
Suneet Agarwal, MD, PhD
This session was presented at the AAMDSIF 2026 International Bone Marrow Failure Scientific Symposium; Co-Chairs Carlos DeCastro, MD, and Phil Scheinberg, MD, PhD. Session topics included: -Androgens, alemtuzumab, anti-cytokine therapies (anti-IL2R, anti-IFN gamma), daratumumab…

Pathways of Clonal Progression Arising from Germline Predisposition, AAMDSIF 2026 International Bone Marrow Failure Scientific Symposium

Thumbnail for video Watch Now

Topic(s)
Acute Myeloid Leukemia (AML)
Myelodysplastic Syndromes (MDS)
Presenter(s)
Marcin Wlodarski, MD, PhD
David Young, MD, PhD
Daria Babushok, MD, PhD
Enrico Attardi, MD, PhD
Felicia Andresen, MD
This session was recorded at the AAMDSIF 2026 International Bone Marrow Failure Scientific Symposium; Co-Chairs, Marcin Wlodarski, MD, PhD, and R. Coleman Lindsley, MD, PhD. Featured topics and Speakers: From Polyclonal to Monoclonal -Trajectories of clonal hematopoiesis in…

Donor T cells on double duty: VCAR33 for AML after transplant

Original Publication Date
Article Source
External Web Content

In this issue of Blood, Mushtaq et al1 report on a phase 1/2 trial (NCT05984199, known as Vor Biopharma trial VBP301) utilizing donor-derived anti-CD33 chimeric antigen receptor–modified (CAR) T cells (VCAR33) in patients with relapsed acute myeloid leukemia (AML) following…

How I select hematopoietic cell donors in the era of posttransplant cyclophosphamide

Original Publication Date
Article Source
External Web Content

Abstract Selection of a hematopoietic progenitor cell donor for allogeneic hematopoietic cell transplantation (HCT) is essential for treatment planning; however, the parameters that define an “optimal” donor in the modern era are not well defined. Historically, donor-recipient…

Subscribe to Acute Myeloid Leukemia (AML)

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.